Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
46
TH.TO Quote, Financials, Valuation and Earnings
Last price:
$4.47
Seasonality move
:
23.62%
Day range:
$4.47 - $4.47
52-week range:
$1.76 - $4.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.86x
P/B ratio:
--
Volume:
--
Avg. volume:
--
1-year change:
86.25%
Market cap:
$205.5M
Revenue:
$117.1M
EPS (TTM):
-$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TH.TO
Theratechnologies, Inc.
|
$30.9M | $0.07 | -6.56% | -91.8% | $7.25 |
|
BHC.TO
Bausch Health Cos., Inc.
|
$3.4B | $0.97 | 6.92% | 375.64% | $6.98 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TH.TO
Theratechnologies, Inc.
|
$4.47 | $7.25 | $205.5M | -- | $0.00 | 0% | 1.86x |
|
BHC.TO
Bausch Health Cos., Inc.
|
$9.49 | $6.98 | $3.5B | 7.11x | $0.00 | 0% | 0.25x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TH.TO
Theratechnologies, Inc.
|
277.86% | -5.504 | 35.93% | 0.53x |
|
BHC.TO
Bausch Health Cos., Inc.
|
102.76% | 0.758 | 636.35% | 0.78x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TH.TO
Theratechnologies, Inc.
|
$18.2M | -$2.8M | -33.9% | -- | -11.28% | $17.8M |
|
BHC.TO
Bausch Health Cos., Inc.
|
$2.3B | $987.5M | 1.47% | -- | 26.74% | $433.6M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
Theratechnologies, Inc. vs. Competitors
-
Which has Higher Returns TH.TO or BHC.TO?
Bausch Health Cos., Inc. has a net margin of -25.17% compared to Theratechnologies, Inc.'s net margin of 6.75%. Theratechnologies, Inc.'s return on equity of -- beat Bausch Health Cos., Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TH.TOTheratechnologies, Inc.72.86% -$0.13 $21.6M BHC.TOBausch Health Cos., Inc.62.59% $0.66 $29.8B -
What do Analysts Say About TH.TO or BHC.TO?
Theratechnologies, Inc. has a consensus price target of $7.25, signalling upside risk potential of 62.19%. On the other hand Bausch Health Cos., Inc. has an analysts' consensus of $6.98 which suggests that it could fall by -26.41%. Given that Theratechnologies, Inc. has higher upside potential than Bausch Health Cos., Inc., analysts believe Theratechnologies, Inc. is more attractive than Bausch Health Cos., Inc..
Company Buy Ratings Hold Ratings Sell Ratings TH.TOTheratechnologies, Inc.0 0 0 BHC.TOBausch Health Cos., Inc.0 7 0 -
Is TH.TO or BHC.TO More Risky?
Theratechnologies, Inc. has a beta of 0.734, which suggesting that the stock is 26.573% less volatile than S&P 500. In comparison Bausch Health Cos., Inc. has a beta of 0.372, suggesting its less volatile than the S&P 500 by 62.787%.
-
Which is a Better Dividend Stock TH.TO or BHC.TO?
Theratechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bausch Health Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theratechnologies, Inc. pays -- of its earnings as a dividend. Bausch Health Cos., Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TH.TO or BHC.TO?
Theratechnologies, Inc. quarterly revenues are $24.9M, which are smaller than Bausch Health Cos., Inc. quarterly revenues of $3.7B. Theratechnologies, Inc.'s net income of -$6.3M is lower than Bausch Health Cos., Inc.'s net income of $249.3M. Notably, Theratechnologies, Inc.'s price-to-earnings ratio is -- while Bausch Health Cos., Inc.'s PE ratio is 7.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theratechnologies, Inc. is 1.86x versus 0.25x for Bausch Health Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TH.TOTheratechnologies, Inc.1.86x -- $24.9M -$6.3M BHC.TOBausch Health Cos., Inc.0.25x 7.11x $3.7B $249.3M
-
Which has Higher Returns TH.TO or COOL.CX?
Core One Labs, Inc. has a net margin of -25.17% compared to Theratechnologies, Inc.'s net margin of --. Theratechnologies, Inc.'s return on equity of -- beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TH.TOTheratechnologies, Inc.72.86% -$0.13 $21.6M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About TH.TO or COOL.CX?
Theratechnologies, Inc. has a consensus price target of $7.25, signalling upside risk potential of 62.19%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Theratechnologies, Inc. has higher upside potential than Core One Labs, Inc., analysts believe Theratechnologies, Inc. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TH.TOTheratechnologies, Inc.0 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is TH.TO or COOL.CX More Risky?
Theratechnologies, Inc. has a beta of 0.734, which suggesting that the stock is 26.573% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock TH.TO or COOL.CX?
Theratechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theratechnologies, Inc. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TH.TO or COOL.CX?
Theratechnologies, Inc. quarterly revenues are $24.9M, which are larger than Core One Labs, Inc. quarterly revenues of --. Theratechnologies, Inc.'s net income of -$6.3M is higher than Core One Labs, Inc.'s net income of --. Notably, Theratechnologies, Inc.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theratechnologies, Inc. is 1.86x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TH.TOTheratechnologies, Inc.1.86x -- $24.9M -$6.3M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns TH.TO or CURE.X.CX?
Biocure Technology has a net margin of -25.17% compared to Theratechnologies, Inc.'s net margin of --. Theratechnologies, Inc.'s return on equity of -- beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TH.TOTheratechnologies, Inc.72.86% -$0.13 $21.6M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About TH.TO or CURE.X.CX?
Theratechnologies, Inc. has a consensus price target of $7.25, signalling upside risk potential of 62.19%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Theratechnologies, Inc. has higher upside potential than Biocure Technology, analysts believe Theratechnologies, Inc. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings TH.TOTheratechnologies, Inc.0 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is TH.TO or CURE.X.CX More Risky?
Theratechnologies, Inc. has a beta of 0.734, which suggesting that the stock is 26.573% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TH.TO or CURE.X.CX?
Theratechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theratechnologies, Inc. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TH.TO or CURE.X.CX?
Theratechnologies, Inc. quarterly revenues are $24.9M, which are larger than Biocure Technology quarterly revenues of --. Theratechnologies, Inc.'s net income of -$6.3M is higher than Biocure Technology's net income of --. Notably, Theratechnologies, Inc.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theratechnologies, Inc. is 1.86x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TH.TOTheratechnologies, Inc.1.86x -- $24.9M -$6.3M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns TH.TO or HEAL.CX?
has a net margin of -25.17% compared to Theratechnologies, Inc.'s net margin of --. Theratechnologies, Inc.'s return on equity of -- beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TH.TOTheratechnologies, Inc.72.86% -$0.13 $21.6M HEAL.CX-- -- -- -
What do Analysts Say About TH.TO or HEAL.CX?
Theratechnologies, Inc. has a consensus price target of $7.25, signalling upside risk potential of 62.19%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Theratechnologies, Inc. has higher upside potential than , analysts believe Theratechnologies, Inc. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings TH.TOTheratechnologies, Inc.0 0 0 HEAL.CX0 0 0 -
Is TH.TO or HEAL.CX More Risky?
Theratechnologies, Inc. has a beta of 0.734, which suggesting that the stock is 26.573% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TH.TO or HEAL.CX?
Theratechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theratechnologies, Inc. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TH.TO or HEAL.CX?
Theratechnologies, Inc. quarterly revenues are $24.9M, which are larger than quarterly revenues of --. Theratechnologies, Inc.'s net income of -$6.3M is higher than 's net income of --. Notably, Theratechnologies, Inc.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theratechnologies, Inc. is 1.86x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TH.TOTheratechnologies, Inc.1.86x -- $24.9M -$6.3M HEAL.CX-- -- -- --
-
Which has Higher Returns TH.TO or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -25.17% compared to Theratechnologies, Inc.'s net margin of --. Theratechnologies, Inc.'s return on equity of -- beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TH.TOTheratechnologies, Inc.72.86% -$0.13 $21.6M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About TH.TO or NSHS.CX?
Theratechnologies, Inc. has a consensus price target of $7.25, signalling upside risk potential of 62.19%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Theratechnologies, Inc. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Theratechnologies, Inc. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TH.TOTheratechnologies, Inc.0 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is TH.TO or NSHS.CX More Risky?
Theratechnologies, Inc. has a beta of 0.734, which suggesting that the stock is 26.573% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock TH.TO or NSHS.CX?
Theratechnologies, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theratechnologies, Inc. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TH.TO or NSHS.CX?
Theratechnologies, Inc. quarterly revenues are $24.9M, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. Theratechnologies, Inc.'s net income of -$6.3M is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Theratechnologies, Inc.'s price-to-earnings ratio is -- while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theratechnologies, Inc. is 1.86x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TH.TOTheratechnologies, Inc.1.86x -- $24.9M -$6.3M NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
